Next 10 |
home / stock / bcli / bcli articles
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results. Biophytis posted a FY23 lo...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) an...
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth...
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition prop...
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discu...
Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pi...
NEW YORK, Dec. 25, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire Bob Dagher , MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NE...
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegener...
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS PR Newswire NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes ...